Given these findings, ACE2 may also be a therapeutic target for MI; however, as no effective drugs can adequately evaluate ACE2 expression in the heart, the concrete molecular mechanisms underlying ACE2 actions need to be further investigated. This evidence concerns the gene ACE2 and myocardial infarction.